Business Model & Revenue
OmniAb operates a pure-play technology licensing business model within the biopharmaceutical ecosystem. The company has engineered a suite of proprietary transgenic animals whose immune systems have been modified to generate fully human antibodies. When pharmaceutical companies want to develop a new targeted therapy, they use OmniAb's Biological Intelligence™ platform to discover optimal antibody candidates efficiently.
The revenue model aligns OmniAb's economic interests directly with its partners. The company generates revenue across three distinct phases of drug development: upfront technology access fees, research and development milestones as the partner's drug progresses through clinical trials, and ultimately tiered royalties on commercial net sales if the drug reaches the market. This structure provides OmniAb with near-term cash flow while capturing high-margin upside.
Financial Highlights
Full-Year / Recent Trailing Performance
| Metric | H1 2026 | H1 2025 | YoY% |
|---|---|---|---|
| Revenue | $27.8M | $8.1M | 243% |
| Net Loss | ($13.6M) | ($34.1M) | 60% (Improvement) |
| EPS | ($0.11) | ($0.32) | 65% (Improvement) |
| Year-End Cash Guide | $51M (Midpt) | N/A | N/A |
Quarterly Progression
| Quarter | Revenue | Net Loss | EPS |
|---|---|---|---|
| Q2 2026 | $13.4M | ($6.5M)* | ($0.05)* |
| Q1 2026 | $14.4M | ($7.1M) | ($0.06) |
| Q4 2025 | $9.2M* | ($10.2M)* | ($0.08)* |
| Q3 2025 | $8.5M* | ($11.5M)* | ($0.10)* |
Balance Sheet Snapshot
| Item | Amount |
|---|---|
| Projected Year-End Cash | $49M - $53M |
| Total Debt | Minimal |
| Float | 107.31M Shares |
Guidance: Year-end 2026 cash is expected at $49M-$53M, up from prior guidance of $37M-$41M, driven by recent licensing activity.
Competitive Landscape
OmniAb operates in the highly specialized niche of antibody discovery platforms, competing against both in-house pharmaceutical research teams and other outsourced discovery engines. While many companies offer antibody discovery, OmniAb differentiates itself through the sheer diversity of its transgenic host systems and its specialized capabilities in difficult targets like ion channels.
- AbCellera Biologics (ABCL): Focuses heavily on AI and microfluidic single-cell screening. AbCellera has strong big-pharma partnerships but relies more heavily on its hardware/software screening advantages rather than transgenic animal diversity.
- Twist Bioscience (TWST): Primarily a synthetic DNA manufacturer that has expanded into antibody discovery using synthetic libraries. Twist offers speed and scale, but synthetic libraries sometimes lack the natural optimization found in in vivo immune responses.
- Ligand Pharmaceuticals (LGND): A broad-based royalty aggregator that spun out OmniAb in 2022. While no longer a direct competitor, Ligand represents the pure financial royalty model that OmniAb aspires to emulate on the technology side.
Durable Competitive Advantages (Moats):
- Transgenic Diversity: Offering mice, rats, and chickens provides a broader array of immune responses, increasing the probability of finding a high-affinity antibody for difficult targets.
- Switching Costs: Once a partner begins a discovery program on OmniAb's platform, the cost and time delay of switching to an alternative platform are prohibitively high.
- Validation Network Effect: Tier-1 partnerships (like the Eli Lilly deal) validate the platform's efficacy, making it easier to sign subsequent partners and command higher upfront fees.
Catalysts
- October 2026 Investor and Analyst Day: The company is slated to provide major business updates and strategic plans, which could prompt analyst upgrades.
- Additional Tier-1 Partnerships: Following the Lilly validation, OmniAb is well-positioned to announce further licensing agreements in H2 2026.
- Clinical Progression of Partnered Assets: Any announcement from existing partners regarding Phase II/III successes or regulatory approvals will unlock lump-sum milestone payments.
Key Risks
- Milestone payments are heavily backloaded and dependent on Eli Lilly's clinical success, meaning near-term cash flow remains minimal.
- The ion channel discovery space is highly competitive, and OmniAb's platform must constantly adapt to remain relevant against evolving alternatives.
- If Eli Lilly abandons the ion channel program, OmniAb will forfeit all remaining milestone payments and royalties without recourse.
- The company continues to operate at a net loss, and failure to sign additional tier-1 partnerships could result in future dilutive capital raises.
- Since OmniAb relies entirely on partners for drug development, it has zero control over clinical timelines, trial design, or regulatory strategy.
Our Thesis
OmniAb represents one of the most compelling "picks and shovels" plays in biotechnology. Instead of burning hundreds of millions on clinical trials, the company licenses its proprietary transgenic animal platforms to pharma giants. The Lilly collaboration for ion channel targets illustrates this leverage: OmniAb incurs minimal incremental cost while gaining exposure to up to $370 million in downstream milestones and recurring royalties. Because ion channels are notoriously difficult targets for traditional drug discovery, Lilly’s reliance on OmniAb’s technology serves as a massive technical endorsement.
The financial trajectory is rapidly accelerating. In Q2 2026, OmniAb reported revenue of $13.4 million, up substantially from $3.9 million in the prior-year period. Crucially, the upfront capital from the Lilly agreement allowed management to raise year-end 2026 cash guidance to a robust $49 million to $53 million. Our $7.50 price target is rooted in a sum-of-the-parts pipeline valuation. Applying a conservative 25% probability of success to the $370M Lilly milestones yields roughly $92M in risk-adjusted value from this single deal alone. When combined with $50M in year-end cash and a base platform business generating ≈$50M in annualized high-margin revenue (valued at 10x forward sales), the intrinsic value easily clears $650M–$750M.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.